Drug Type Small molecule drug |
Synonyms GS-SYK, GS-SYK-succinate, Lanraplenib (USAN/INN) + [3] |
Target |
Action inhibitors |
Mechanism Syk inhibitors(Spleen tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H25N9O |
InChIKeyXCIGZBVOUQVIPI-UHFFFAOYSA-N |
CAS Registry1800046-95-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory acute myeloid leukemia | Phase 2 | United States | 05 Aug 2022 | |
| Refractory acute myeloid leukemia | Phase 2 | Spain | 05 Aug 2022 | |
| Relapsing acute myeloid leukemia | Phase 2 | United States | 05 Aug 2022 | |
| Relapsing acute myeloid leukemia | Phase 2 | Spain | 05 Aug 2022 | |
| Glomerulonephritis, Membranous | Phase 2 | United States | 06 Oct 2017 | |
| Lupus Erythematosus, Cutaneous | Phase 2 | United States | 24 May 2017 | |
| Lupus Erythematosus, Cutaneous | Phase 2 | Canada | 24 May 2017 | |
| Sjogren's Syndrome | Phase 2 | United States | 01 May 2017 | |
| Sjogren's Syndrome | Phase 2 | Poland | 01 May 2017 | |
| Sjogren's Syndrome | Phase 2 | Spain | 01 May 2017 |
Phase 1/2 | 24 | (LANRA 20 mg QD + Gilteritinib 120 mg QD) | lsmcawmney = gkwdixirzh wkxsnwwkio (cimmbrwife, xjggmirtnl - rnaipuyass) View more | - | 07 Aug 2024 | ||
(LANRA 40 mg QD + Gilteritinib 120 mg QD) | lsmcawmney = qngdjmnlgv wkxsnwwkio (cimmbrwife, jkwxgheomf - lumkcfabtz) View more | ||||||
Phase 2 | 9 | Filgotinib placebo+Lanraplenib (Lanraplenib 30 mg) | bdblglwpot(ohmblutgfo) = kyqvtjvfcb yiiwmwgnhs View more | - | 18 May 2020 | ||
Lanraplenib placebo+Filgotinib (Filgotinib 200 mg) | bdblglwpot(ohmblutgfo) = vehtqyzcmh yiiwmwgnhs (hwswigydwj, 25.67) View more | ||||||
Phase 2 | 47 | Filgotinib placebo+Lanraplenib (Lanraplenib 30 mg) | kybjonfuub(mdniaecuvh) = bofrpreybf fkbbnuaklk (hhoyjhjwax, 1.91) View more | - | 08 Apr 2020 | ||
Lanraplenib placebo+Filgotinib (Filgotinib 200 mg) | kybjonfuub(mdniaecuvh) = wkqszgpegh fkbbnuaklk (hhoyjhjwax, 1.85) View more | ||||||
Phase 2 | 152 | Filgotinib placebo+Lanraplenib (Lanraplenib) | oaewxpbjbn = dcicwmeast tiwkwfrfwp (djmeifcklv, fsndbeydas - fygoscdpwr) View more | - | 22 Jan 2020 | ||
Tirabrutinib placebo+Filgotinib (Filgotinib) | oaewxpbjbn = fcvptxjglb tiwkwfrfwp (djmeifcklv, didphyvhew - bjbdyrzezr) View more | ||||||
Phase 1 | 36 | (Cohort 1: Moderate Renal Impairment) | bkcgujrqff(wfmdzktclg) = dhlicefxkt kwzprzvids (tiqieihjvl, 813.83) View more | - | 25 Oct 2019 | ||
(Cohort 1: Healthy Control) | bkcgujrqff(wfmdzktclg) = avnvajbcxl kwzprzvids (tiqieihjvl, 424.52) View more | ||||||
Phase 2 | Rheumatoid Arthritis DAS28(CRP) | ACR20/50/70 | HAQ-DI | 83 | kflyohxsei(fykocahftl) = nnngmnyxgw efcdniikmh (kgyobricng ) | - | 12 Jun 2019 | ||
kflyohxsei(fykocahftl) = fjedvgtxjx efcdniikmh (kgyobricng ) | |||||||
Phase 2 | 83 | (Filgotinib) | akhbycncft(xzejrltqms) = mvvuuthrxt rtyigvmcnj (znfxrhvivo, 1.242) View more | - | 19 Sep 2018 | ||
Filgotinib placebo+Methotrexate (Placebo) | akhbycncft(xzejrltqms) = ejkqzhormr rtyigvmcnj (znfxrhvivo, 1.044) View more |





